News for Healthier Living

PI3K-Driven Wild-Type RAS Activation Fuels KRAS Inhibitor Resistance

This study investigates how PI3K enables pancreatic cancer cells to resist KRAS inhibitors by activating wild-type RAS signaling, suggesting combined PI3K-KRAS targeting as a therapeutic strategy.

May 31, 2026


June 5 2026

June 4 2026

June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026